Funding for this research was provided by:
National Institute on Drug Abuse (5 R01 DA035879-04)
Received: 13 March 2017
Accepted: 11 July 2017
First Online: 10 August 2017
Ethics approval and consent to participate
: Participation was voluntary. The study received approval from the Chestnut Health Systems’ Institutional Review Board (IRB Study No. 1091-0114) and is registered at Clinical Trials.gov (NCT02132481). Chestnut’s IRB acted as a Centralized Ethics Committee for the two substance use treatment agencies from which participants were recruited. The study complies with the relevant Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and World Health Organization (WHO) Checklist (see Additional file InternalRef removed).
: Informed written consent was received for publication of the manuscript and figures. The Consent Form is held by the authors and their institution and is available for review by the Editor-in-Chief.
: Author Dr. Gustafson has a shareholder interest in CHESS Mobile Health, a small business that develops web-based health care technology for patients and family members. This relationship is extensively managed by the authors and the University of Wisconsin. All other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.